Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adaptimmune Therapeutics ( (ADAP) ) just unveiled an update.
On September 11, 2025, Adaptimmune Therapeutics received a notice from Nasdaq indicating that its market value of listed securities had fallen below the $35 million minimum required for continued listing. The company has until March 10, 2026, to regain compliance, failing which its securities may be delisted from Nasdaq. The notice does not immediately affect the trading of its American Depositary Shares, but the company is exploring options to meet the compliance requirements.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Spark’s Take on ADAP Stock
According to Spark, TipRanks’ AI Analyst, ADAP is a Underperform.
Adaptimmune Therapeutics’ overall stock score is primarily driven by its weak financial performance and valuation metrics. The technical analysis indicates bearish momentum, further contributing to the low score. The absence of positive earnings call insights or corporate events leaves the stock with limited upside potential in the near term.
To see Spark’s full report on ADAP stock, click here.
More about Adaptimmune Therapeutics
Adaptimmune Therapeutics plc operates in the biotechnology industry, focusing on the development of T-cell therapies for cancer treatment.
Average Trading Volume: 37,163,882
Technical Sentiment Signal: Sell
Current Market Cap: $13.39M
For detailed information about ADAP stock, go to TipRanks’ Stock Analysis page.